Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.
Choudhury SR, Harris AF, Cabral DJ, Keeler AM, Sapp E, Ferreira JS, Gray-Edwards HL, Johnson JA, Johnson AK, Su Q, Stoica L, DiFiglia M, Aronin N, Martin DR, Gao G, Sena-Esteves M
Mol Ther. 2015 Dec 28. doi: 10.1038/mt.2015.231. PubMed Article
Choudhury SR, Harris AF, Cabral DJ, Keeler AM, Sapp E, Ferreira JS, Gray-Edwards HL, Johnson JA, Johnson AK, Su Q, Stoica L, DiFiglia M, Aronin N, Martin DR, Gao G, Sena-Esteves M
Mol Ther. 2015 Dec 28. doi: 10.1038/mt.2015.231. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 74237 | pGG-9.47_VP1,3 #2515 | Modified plasmid with a different backbone that yields higher of AAV-AS vectors. Encodes VP1 and VP3 of AAV9.47 |
| 74238 | pGG-9.47_VP2_AS #2562 | Modified plasmid with a different backbone that yields higher titers of AAV-AS vectors. Encodes VP2-AS chimeric protein with 19 alanines fused to N-terminus of AAV9.47 VP2. |
| 74240 | pAR-9.47_VP1,3 | Original plasmid described in Choudhury et al. 2015 Mol Ther. for production of AAV-AS vectors. Encodes VP1 and VP3 of AAV9.47 |
| 74241 | pAR-9.47_VP2_AS | Original plasmid described in Choudhury et al, 2015 Mol. Ther. for production of AAV-AS vectors. Encodes VP2_AS chimeric protein with 19 alanines fused to the N-terminus of AAV9.47 VP2. |